Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment

Pancreatic ductal adenocarcinoma remains an aggressive cancer with a low 5-year survival rate. Although gemcitabine has been a standard treatment for advanced pancreatic cancer, patients often develop resistance to this therapeutic. We have previously shown that treating pancreatic cancer cells in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Rimmer, Ella, Rashid, Sadaf, Kraev, Igor, Miralles, Francesc, Elia, Androulla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317709/
https://www.ncbi.nlm.nih.gov/pubmed/35887158
http://dx.doi.org/10.3390/ijms23147810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317709/
https://www.ncbi.nlm.nih.gov/pubmed/35887158
http://dx.doi.org/10.3390/ijms23147810

Ejemplares similares